Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:HIMS News 9 January 2026 - 6 February 2026

Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Hims & Hers Health shares fell 3.8% to $23.48 in premarket trading Friday after FDA Commissioner Marty Makary warned of a crackdown on “illegal copycat drugs.” The drop followed Hims’ launch of a $49 compounded version of Novo Nordisk’s Wegovy pill. Novo Nordisk said it would pursue legal and regulatory action, calling Hims’ move “illegal mass compounding.” Investors are watching for FDA enforcement and lawsuits ahead of Hims’ Feb. 23 report.
6 February 2026
······
Hims & Hers (HIMS) stock whipsaws on $49 “compounded Wegovy pill” plan as Novo Nordisk threatens legal action

Hims & Hers (HIMS) stock whipsaws on $49 “compounded Wegovy pill” plan as Novo Nordisk threatens legal action

Hims & Hers Health shares surged to $29.44 before falling back to $24.41 after announcing $49 compounded semaglutide pills. Novo Nordisk said it will sue, calling the move illegal mass compounding. The FDA previously warned Hims about misleading claims on compounded semaglutide. Novo’s branded Wegovy pill will cost $199 per month.
5 February 2026
······
Hims & Hers Health (HIMS) stock slides premarket after Amazon’s Wegovy pill move — what traders watch next

Hims & Hers Health (HIMS) stock slides premarket after Amazon’s Wegovy pill move — what traders watch next

NEW YORK, Jan 12, 2026, 05:28 EST — Premarket Shares of Hims & Hers Health, Inc. slipped 2.2% in premarket trading Monday, hitting $31.00. The stock had already fallen 6.4% on Friday to $31.69 amid heavy volume. (StockAnalysis) The selloff late in the week came after Amazon Pharmacy began offering Novo Nordisk’s newly approved Wegovy weight-loss pill via insurance plans and a cash-pay option, opening yet another major channel in a market Hims has heavily relied on for growth. (Reuters) This is crucial now since investors see weight loss as Hims’ key growth driver: it attracts fresh users but can
12 January 2026
····
Hims & Hers stock slides as Amazon adds Wegovy pill, raising fresh pricing fears

Hims & Hers stock slides as Amazon adds Wegovy pill, raising fresh pricing fears

NEW YORK, Jan 10, 2026, 06:23 EST — Market closed Hims & Hers Health, Inc. (HIMS) shares fell 6.4% on Friday to $31.69, with about 25 million shares changing hands. The stock is down roughly 11% over the past two sessions as investors weighed Amazon Pharmacy’s move into Novo Nordisk’s Wegovy weight-loss pill business. (StockAnalysis) That matters now because Hims has pushed hard into GLP-1 weight-loss drugs — medicines that mimic a gut hormone to curb appetite — and a lot of demand in the category still comes from patients paying cash. Hims lists a “compounded GLP-1” program starting at
10 January 2026
·····
Hims & Hers stock slides as Amazon starts selling Novo Nordisk’s new Wegovy pill

Hims & Hers stock slides as Amazon starts selling Novo Nordisk’s new Wegovy pill

New York, Jan 9, 2026, 15:52 EST — Regular session Shares of Hims & Hers Health, Inc (HIMS.N) fell 5.3% to $32.06 on Friday, after Amazon Pharmacy said it now offers Novo Nordisk’s Wegovy weight-loss pill, raising the pressure on telehealth sellers chasing obesity drug demand. The stock hit an intraday high of $34.35 before sliding to a session low of $32.06. (Reuters) The move matters because weight-loss has become a key battleground for online healthcare platforms, and the market has started to treat GLP-1 drugs — medicines that can curb appetite and drive weight loss — as a price
9 January 2026
····

Stock Market Today

Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

7 February 2026
London, February 7, 2026, 08:46 GMT — Market closed. Vodafone shares closed at 110.60p on Friday, up 1.47%, clawing back some ground after a 4.68% slide on Thursday. (Investing.com) The whipsaw came after Vodafone’s fiscal third-quarter trading update, where the company said it was still on track to land at the upper end of its profit and cash-flow guidance for the year ending in March. (Investegate) That matters because Vodafone has been leaning hard on tighter execution and shareholder returns to keep the re-rating alive — including fresh buybacks — while it tries to rebuild momentum in Germany, its biggest
NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

7 February 2026
NatWest shares closed up 1.45% at 659.4 pence Friday, buoyed by a buyback of 797,428 shares and a new digital mortgage deal with Rightmove. The Bank of England held rates at 3.75% but signaled possible cuts, with markets pricing in two reductions for 2026. NatWest plans to expand its Accelerator community to 50,000 members by 2026. Annual results are due Feb. 13.
Unilever share price holds at 5,250p as results week looms — what investors watch next

Unilever share price holds at 5,250p as results week looms — what investors watch next

7 February 2026
Unilever shares closed flat at 5,250p in London Friday, underperforming the FTSE 100’s 0.6% gain. The company issued 4.2 million new shares for employee plans, bringing total shares to over 2.18 billion. Investors await Q4 and full-year results on Feb. 12, with analyst consensus pointing to 3.9% Q4 sales growth. Unilever’s U.S. ADR rose 0.8% to $72.12.
BP share price near 52-week high ahead of Feb 10 earnings as buyback runs on

BP share price near 52-week high ahead of Feb 10 earnings as buyback runs on

7 February 2026
BP shares closed up 1.9% at 478 pence Friday, just below a 52-week high, as the company continued buybacks ahead of next week’s results. BP repurchased 2.789 million shares on February 6. Oil prices firmed on geopolitical risk, with Brent at $68.05 a barrel, but sector outlook remains uncertain. Investors await BP’s earnings and dividend decision due Tuesday.
Go toTop